Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, ...
100% (19/19) patients achieved minimal residual disease negative stringent complete response (MRD- sCR) SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gracell ...
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 6, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (GRCL), a global clinical-stage biopharmaceutical company dedicated to developing ...
Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk ...
GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of autoantibodies producing B-cells and plasma cells SLE is a chronic autoimmune disease, in ...
Gracell Bio stands to benefit from tax credits and marketing exclusivity following receipt of ‘orphan drug’ status for its CAR-T cancer treatment Analysts see profitability several years away as ...
GC012F, a FasTCAR-enabled autologous CAR-T cell therapy, is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune disease SAN DIEGO and SUZHOU, China ...
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results